This excerpt taken from the NVO 6-K filed Feb 9, 2007.
This is Novo Nordisks Annual
Report 2006. It accounts for the companys
performance during the year and presents achievements and challenges. We
trust you will find that we have done so in a fair and balanced way.
People at Novo Nordisk are guided by the companys
vision and its values. There is a strong sense of shared purpose across the
organisation, and a commitment to pursuing the goals set out in the vision:
to achieve competitive business results, to sustain leadership in diabetes
care, to expand the biopharmaceuticals business, to be a challenging workplace,
and to put values into action.
This years Annual Report seeks to
capture the essence of the Novo Nordisk way. It illustrates how we do business
and explains how we will continue to create long-term shareholder value.
The management report and discussion presents an
overview of business performance during 2006 with highlights, five-year developments
and a commentary.
The feature articles put performance into context.
Organised under the visions five headings, they provide insights into activities
during the year, strategies and goals, risks and opportunities. The articles
reflect the key priorities for Novo Nordisk and topics that we have identified
as material for readers valuation of the companys position for the
You will find a more detailed account of performance
in the consolidated financial and non-financial statements.
the shareholder information presents Novo Nordisks corporate governance
model, and the approach to risk management, and examples of the current
risk profile. Here you will also find profiles of the members of the Board
of Directors and Executive Management. And if you are looking for information
about the share, begin reading from the back.
Action defines leadership
Working with Novo Nordisk, you will learn
what it means to be a values-led company. Our values underpin the commitments,
principles and policies that form our global standards for doing business.
In everything we do, we will be accountable, ambitious, responsible,
engaged with stakeholders, open and honest, and ready for change.
The pictures tell stories of Novo Nordisk people
putting these values into action. Action defines leadership. Every day of
the year, across the globe, people at Novo Nordisk bring to life what leadership
is all about.
Our aspiration is to defeat diabetes. It is an
ambitious goal, yet we believe it can be achieved. Working with stakeholders,
driving concerted action and thinking out of the box, Novo Nordisk is changing
diabetes. This report provides some examples. To learn more, or to get involved
in some of the work, please get in touch.
A year in the life of Novo Nordisk
Factory expansion 11January: A factory expansion
inClayton, North Carolina, results
in doubled insulin filling capabilities, a new assembly and packaging line,
and administration and storage space. Page 12.
Goodbye to an icon 8 March: Outgoing Chairman of
the Board Mads Øvlisen, a Novo Nordisk icon, bids farewell to shareholders
at the Annual General Meeting. Sten Scheibye takes over as Chairman of the
Natural killer cells 5 April: Novo Nordisk and Innate
Pharma SA announce partnership to develop medicines targeting one of the
bodys first lines of defence against cancer and infections: natural
killer cells. Pages
Climate agreement 23 January: Novo Nordisk and the
World Wide Fund for Nature sign an agreement in which the company pledges
to reduce its CO2 emissions. Page 48.
CEO rings closing bell at the NYSE 7 February: Novo Nordisk celebrates
the 25th anniversary of the companys listing on the exchange. Pages
US research facility opens 21 February: Opening of Novo Nordisk
Research US, the first haemostasis research facility in the United States
dedicated to life-threatening bleeding. Page 37.
R&D agreement 14 March: Argos Therapeutics
and Novo Nordisk announce agreement to develop treatment for systemic autoimmune
US launch of Levemir® 28 March: Announcement of
the US commercial availability of Levemir®, a long-acting
modern insulin. Pages 2425.
EU leaders prioritise
diabetes 24 April: The European Parliament
passes a Novo Nordisk-supported declaration calling for increased focus
on diabetes. Pages 2829.